A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis(FRONTIER 4)

Project Details

StatusActive
Effective start/end date1/07/211/07/23

Funding

  • AstraZeneca: AUD28,500.00
  • AstraZeneca: AUD28,500.00
  • AstraZeneca: AUD28,500.00
  • AstraZeneca